Lorlatinib (Lorbrexen) 100mg Tablets | ALK/ROS1 Inhibitor Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

مشاركة
Product description

Generic Information: Lorbrexen (Lorlatinib)

Lorbrexen is a generic formulation of lorlatinib, a third-generation, brain-penetrant ALK and ROS1 tyrosine kinase inhibitor. Lorlatinib is designed to cross the blood-brain barrier and to inhibit both wild-type ALK and resistance mutations including G1202R, making it a key treatment for ALK-positive non-small cell lung cancer (NSCLC), including patients with brain metastases. Lorbrexen is manufactured by Everest Pharmaceuticals under GMP-certified conditions and supplied by GIVE LIFE TIME LIMITED (GLT).

What Is Lorbrexen (Lorlatinib) Used For?

Lorbrexen (lorlatinib) is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), both as first-line therapy and after disease progression on prior ALK inhibitors. Its excellent central nervous system penetration makes it especially valuable for patients with brain metastases or those at risk of CNS progression.

In the pivotal phase III CROWN trial, lorlatinib achieved a median progression-free survival beyond three years (3-year PFS rate of 63.5%), with an intracranial objective response rate of 83.3% in patients with measurable brain metastases.

How Does Lorbrexen (Lorlatinib) Work?

Lorlatinib is a macrocyclic kinase inhibitor that selectively targets ALK and ROS1. Engineered for high CNS penetration, it remains active against ALK resistance mutations including G1202R that emerge after earlier-generation ALK inhibitors. By blocking ALK/ROS1 signalling, it suppresses tumour cell proliferation and survival, delivering durable systemic and intracranial disease control.

Indications

  • ALK-positive metastatic non-small cell lung cancer (NSCLC)
  • Effective against ALK resistance mutations including G1202R
  • Active in patients with brain metastases

Dosage & Administration

The recommended dose is 100 mg once daily, with or without food. Tablets should be swallowed whole. The 25 mg strength is used for dose modification. Treatment must be initiated and supervised by an experienced oncologist.

Side Effects

Common adverse reactions include edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, hypercholesterolemia, hypertriglyceridemia, diarrhoea and cough. Patients should be monitored for hyperlipidemia, hypertension, hyperglycemia, central nervous system effects and interstitial lung disease. Concomitant strong CYP3A inducers are contraindicated.

Storage

Store at controlled room temperature in the original packaging, protected from light and moisture. Ambient (non-cold-chain) shipping is suitable for oral tablets.

Why Choose the GLT?

  • Authentic, GMP-certified sourcing — Everest Pharmaceuticals manufactures Lorbrexen under GMP conditions with full batch documentation.
  • Affordable access — generic lorlatinib offers a significantly lower cost per cycle than originator Lorbrena.
  • Same mechanism, same efficacy — lorlatinib targets ALK/ROS1 with brain penetration and activity against G1202R.
  • Reliable supply by GLT — GIVE LIFE TIME LIMITED ships with CoA, CPP and batch traceability worldwide.

How to Order Lorbrexen (Lorlatinib) from GLT?

  1. Contact us via WhatsApp +86 15234153837 or email [email protected] with the product name, specification and quantity.
  2. Receive a formal quotation, payment instructions and estimated delivery time.
  3. Complete payment via our secure payment channel (Hao Yi Lian / 好易联).
  4. Goods are dispatched with batch documentation; tracking provided until delivery.

We serve both licensed institutions and individual patients. A valid prescription may be requested before dispatch.

FAQ

1. What strengths are available?

Lorbrexen is available in 25 mg × 30 and 100 mg × 30 tablets. The recommended dose is 100 mg once daily.

2. Does lorlatinib work against brain metastases?

Yes. Lorlatinib is designed for high CNS penetration and shows strong intracranial activity.

3. How is it shipped internationally?

As an oral tablet, Lorbrexen ships via ambient courier with full documentation. Typical delivery is 7–14 days.

4. Can I order for personal use?

GLT serves institutions and individual patients. Individual buyers should hold a valid prescription.

Related Oncology Products

أورفورغليبرون (لوسيورفور) أقراص 0.8–17.2 ملغ | دواء جينيريك لاوسي فموي GLP-1 | GLT

جينيريك أورفورغليبرون من Lucius Pharmaceuticals (لاوس)، نظام معايرة من 6 جرعات لإدارة الوزن

بارينيب (باريسيتينيب) 2ملغ | مثبط JAK1/JAK2 جنيس | دراغ إنترناشيونال المحدودة | GLT

باريسيتينيب جنيس (مثبط JAK1/JAK2) من دراغ إنترناشيونال المحدودة (بنغلاديش) — بديل ميسور التكلفة عن أولوميانت...

كيزيروي 科瑞泽 (أفاترومبوباغ) 20ملغ*10 أقراص | سيتشوان كيلون (الصين) | GLT

كيزيروي — أفاترومبوباغ المشتريات الوطنية من سيتشوان كيلون للأدوية، الشركة الصينية المتكاملة لتصنيع المادة الفعالة...

لوسيافات (أفاترومبوباغ) 20ملغ*28 قرصاً | لوسيوس للأدوية (لاوس) | GLT

لوسيافات — أقراص أفاترومبوباغ 20ملغ (ماليات 23.6ملغ) مطلية بغشاء من لوسيوس للأدوية (لاوس) المحدودة، فيينتيان.

KangQuXin 康曲欣 (أفاترومبوباغ) 20 ملغ × 10 أقراص | Beijing Continent (Gyre) | GLT

KangQuXin — أفاترومبوباغ من Beijing Continent Pharmaceutical (Gyre Therapeutics، ناسداك: GYRE)، الصين

Avabopa (أفاترومبوباغ) 20 مجم × 30 قرص | Tongmeng TLPH لاوس | GLT

Avabopa — أفاترومبوباغ 20 مجم من Tongmeng (Lao) Pharmaceutical and Food Co., Ltd. (TLPH)، تسجيل...

بارينات (باريسيتينيب) 4ملغ | مثبط JAK1/JAK2 جنيس | ناتكو فارما المحدودة | GLT

باريسيتينيب جنيس (مثبط JAK1/JAK2) من ناتكو فارما المحدودة (الهند) — بديل ميسور التكلفة عن أولوميانت...

أفاتودكس (أفاترومبوباغ) 20ملغ*30 قرصاً | بيغبير للأدوية (لاوس) | GLT

أفاتودكس — أفاترومبوباغ 20ملغ من بيغبير للأدوية (لاوس) المحدودة، رقم تسجيل لاوس 06L0985/23، زجاجة من...